medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2014, Number 1

<< Back Next >>

Acta Med 2014; 12 (1)

Screening for critical congenital heart disease. Latest recommendations

Cullen BPJ, Guzmán CB

Language: Spanish
References: 26
Page: 24-29
PDF size: 150.51 Kb.


ABSTRACT

The screening practice in newborn infants started on 1963 with the detection of phenylketonuria by Dr. Robert Guthrie and it has extended to other metabolic pathologies. Since the mid 70’s more nations are incorporating screening programs to their public health policies. These programs must comply with the World Health Organization cost-benefit criteria known as the Gunner-Jungner criteria. In recent years many countries and the American Academy of Pediatrics have stated a new recommendation for critical congenital heart disease screening. It is based on the use of pulse oximetry in every apparently healthy newborn after 24 hours of birth; it is an excellent prevention instrument for the early detection of subclinical congenital heart disease.


REFERENCES

  1. Guthrie R. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963; 32: 338-343.

  2. Wilson JMG, Jungner F. Principles and practice of screening for disease. Public Health Papers. 1968; 34: 163.

  3. Naylor EW, Guthrie R. Newborn screening for maple syrup urine disease (Branched-Chain Ketoaciduria). Pediatrics. 1978; 61: 262-266.

  4. Dussault JH, Coulombe P, Laberge C, Letarte J, Guyda H, Khoury K. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr. 1975; 86: 670-674.

  5. Sweetman L. Newborn screening by tandem mass spectrometry (MS/MS). Clin Chem. 1996; 42: 345-346.

  6. Velázquez A, Loera A, Aguirre BE, Gamboa S, Vargas H, Robles C. Tamiz neonatal para hipotiroidismo congénito y fenilcetonuria. Salud Pública de Mex. 1994; 36: 249-256.

  7. Norma Oficial Mexicana NOM-034-SSA2-2002. Para la prevención y control de los defectos al nacimiento. Diario Oficial de la Federación, México D.F., lunes 23 de octubre de 2003.

  8. Barba EJR. Tamiz Neonatal. Una estrategia preventiva. Rev Mex Patol Clínica. 2004; 51: 130-144.

  9. Torres-Sepúlveda MR, Martínez-de Villarreal LE, Esmer C, González-Alanís R, Ruiz-Herrera C, Sánchez-Peña A et al. Tamiz metabólico
neonatal por espectrometría de masas en tándem: dos años de experiencia en Nuevo León, México. Salud Pública Mex. 2008; 50: 200-206.

  10. Delaney A, Meyers A. Newborn hearing screening. Medscape Reference [Internet]. Available in: http://emedicine.medscape.com/article/836646-overview#a30

  11. US Preventive Services Task Force. Universal screening for hearing loss in newborns: US Preventive Services Task Force recommendation statement. Pediatrics. 2008; 122: 143-148.

  12. Secretaría de Salud. Programa de Acción Específico 2007-2012. Tamiz auditivo neonatal e intervención temprana.

  13. Boneva RS, Botto LD, Moore CA, Yang Q, Correa A, Erickson JD. Mortality associated with congenital heart defects in the United States: trends and racial disparities. Circulation. 2001; 103: 2376-2381.

  14. McConnell ME, Elixson EM. The neonate with suspected congenital heart disease. Crit Care Nurse Q. 2002; 25: 17-25.

  15. Cottrill CM. Congenital heart disease. En: Gomella TL, Eyal FG, Zenk KE. Neonatology: Management, procedures, on-call problems, diseases, and drugs. Fifth ed. Philadelphia: Lange Medical Books. 2004. pp. 354.

  16. www.sinais.salud.gob.mx

  17. Calderón-Colmenero J, Cervantes-Salazar JL, Curi-Curi PJ, Ramírez Marroquín S. Problemática de las cardiopatías congénitas en México. Propuesta de regionalización. Arch Cardiol Mex. 2010; 80: 133-140.

  18. Mellander M, Sunnegardh J. Failure to diagnose critical heart malformations in newborns before discharge-an increasing problem? Acta Paediatr. 2006; 95: 407-413.

  19. Mahle WT, Newburger JW. Role of pulse oximetry in examining newborn for congenital heart disease: a scientific statement from the AHA and AAP. Pediatrics. 2009; 124: 823-836.

  20. Kemper AR, Mahle WT. Strategies for implementing screening for critical congenital heart disease. Pediatrics. 2011; 128: e1259-e1267.

  21. Riede FT, Wörner C, Dähnert I, Möckel A, Kostelka M, Schneider P. Effectiveness of neonatal pulse oximetry screening for detection of critical congenital heart disease in daily clinical routine— Results from a prospective multicenter study. Eur J Pediatr. 2010; 169: 975-981.

  22. De-Wahl GA, Wennergren M, Sandberg K, Mellander M, Bejlum L, Inganäs L et al. Impact of pulse oximetry on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009; 338: a3037.

  23. Mahle WT, Martin GR, Beekman RH, Morrow WR, Rosenthal GL, Section on Cardiology and Cardiac Surgery Executive Committee et al. Endorsement of health and human services recommendation for pulse oximetry screening for critical congenital heart disease. Pediatrics. 2012; 129: 190-192.

  24. Alabama Department of Public Health. Hospital guidelines for implementing pulse oximetry screening for critical congenital heart disease. Montgomery, AL. March, 2012.

  25. Singh A, Ewer KA. Pulse oximetry screening for critical congenital heart defects: a UK national survey. The Lancet. 2013; 381: 535.

  26. Granelli AdW. Near uniform adoption of pulse oximetry screening for critical congenital heart defects in Sweden. BMJ. 2013; 338: a3037. Available in: http://www.bmj.com/content/338/bmj.a3037/rr/639197




2020     |     www.medigraphic.com